The granting of U.S. Patent #11925658 to NuCana for 'Phosphoramidate Derivatives for Use in the Treatment of Cancer' is a significant development for the company. This patent not only strengthens NuCana's intellectual property portfolio but also enhances its position in the oncology sector, particularly in the areas of leukemia, prostate, lung, and breast cancers. Given the broad applicability of the patent for treatments, especially in cases where patients show resistance to existing therapies, this could lead to increased interest and investment in NuCana's research and development efforts. Consequently, this development is likely to have a positive short-term impact on NuCana's stock price as investors react to the potential for new, patented treatments that could lead to significant revenue streams in the future.